Rigel Pharmaceuticals | RIGL - Debt


Rigel Pharmaceuticals reported $59.69M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Celldex Therapeutics USD 2.62M 410K Sep/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Veracyte USD 40.45M 10.19M Sep/2025